文献
J-GLOBAL ID:201802288342282712
整理番号:18A0527400
細胞内アンフィレギュリンEGFR-TKIに対する肺腫瘍細胞の抵抗性に寄与するによるIGF1Rの核転座【Powered by NICT】
Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI
著者 (16件):
Guerard Marie
(Team “RNA splicing, cell signalling and response to therapies”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Guerard Marie
(Team “Cancer targets and experimental therapeutics”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Robin Thomas
(Team “RNA splicing, cell signalling and response to therapies”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Robin Thomas
(Team “Cancer targets and experimental therapeutics”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Perron Pascal
(Team “RNA splicing, cell signalling and response to therapies”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Perron Pascal
(Team “Cancer targets and experimental therapeutics”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Hatat Anne-Sophie
(Team “RNA splicing, cell signalling and response to therapies”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
David-Boudet Laurence
(Grenoble Univ. Hospital, 38000 Grenoble France)
,
Vanwonterghem Laetitia
(Team “Cancer targets and experimental therapeutics”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Busser Benoit
(Team “Cancer targets and experimental therapeutics”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Busser Benoit
(Grenoble Univ. Hospital, 38000 Grenoble France)
,
Coll Jean-Luc
(Team “Cancer targets and experimental therapeutics”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Lantuejoul Sylvie
(Grenoble Univ. Hospital, 38000 Grenoble France)
,
Eymin Beatrice
(Team “RNA splicing, cell signalling and response to therapies”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Hurbin Amandine
(Team “Cancer targets and experimental therapeutics”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
,
Gazzeri Sylvie
(Team “RNA splicing, cell signalling and response to therapies”, Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France)
資料名:
Cancer Letters
(Cancer Letters)
巻:
420
ページ:
146-155
発行年:
2018年
JST資料番号:
E0606B
ISSN:
0304-3835
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)